TNGX

Tango Therapeutics, Inc.

10.04 USD
+0.49 (+5.13%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Tango Therapeutics, Inc. stock is up 35.86% since 30 days ago. The next earnings date is Aug 5, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 75% of the previous 3 June’s closed higher than May. 100% of analysts rate it a buy.

About Tango Therapeutics, Inc.

Tango Therapeutics, Inc. discovers and develops drugs for the treatment of cancer. Lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. Company also develops Ubiquitin-specific protease 1 and Target 3 for STK11-mutant cancers.

  • HC Wainwright & Co.
    Tue May 28, 06:39
    buy
    confirm
  • Guggenheim
    Fri May 24, 12:29
    buy
    confirm
  • Barclays
    Fri May 24, 10:54
    buy
    confirm
  • Wedbush
    Thu May 23, 12:34
    buy
    confirm